Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain

References

• Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41:1–9.
   Web of Science ®Google Scholar
• Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018;47:14–26.
   PubMed Web of Science ®Google Scholar
• de Sanjosé S, Serrano B, Tous S, Alejo M, Lloveras B, Quirós B, Clavero O, Vidal A, Ferrándiz-Pulido C, Pavón MÁ, et al. Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr. 2018;2(4).
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Guidance on HPV vaccination in EU countries : focus on boys, people living with HIV and 9-valent HPV vaccine introduction. [Internet]. Stockholm; 2020. https://www.ecdc.europa.eu/en/publications-data/guidance-hpv-vaccination-eu-focus-boys-people-living-hiv-9vHPV-vaccine.
   Google Scholar
• Linertová R, Guirado-Fuentes C, Mar Medina J, Imaz-Iglesia I, Rodríguez-Rodríguez L, Carmona-Rodríguez M. Cost-effectiveness of extending the HPV vaccination to boys: a systematic review. J Epidemiol Community Health. 2021;75:910–16.
   PubMed Web of Science ®Google Scholar
• De La Fuente J, Hernandez Aguado JJ, Martín MS, Boix PR, Cedillo S, López N. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain. Hum Vaccin Immunother. 2019;5515:1–13.
   Google Scholar
• López Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, Puig-Junoy J. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. Gac Sanit. 2010;24:154–70.
   PubMed Web of Science ®Google Scholar
• Health Information and Quality Authority (HIQA). Health technology assessment (HTA) of extending the national immunisation schedule to include HPV vaccination of boys. Dublin: Health Information and Quality Authority; 2018.
   Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29:8443–50.
   PubMed Web of Science ®Google Scholar
• Jiménez E, Torkilseng EB, Klemp M. Cost-effectiveness of HPV-vaccination of boys aged 12 in a Norwegian setting. Oslo: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2015.
   Google Scholar
• Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch F, and de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in Spain. Summary report 2021 Oct 22.
   Google Scholar
• Baili P, Di Salvo F, Marcos-Gragera R, Siesling S, Mallone S, Santaquilani M, Micheli A, Lillini R, Francisci S, Hackl M, et al. Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: results of EUROCARE-5, a population-based study. Eur J Cancer. 2015;51(15):2120–29.
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estadística (INE). Proyecciones de población - Últimos datos.2019 [accessed 2019]. https://www.ine.es/INEbase/DemografíINEbase/DemografíA y población/Cifras de población y Censos demográficos/proyecciones de población/Últimos datos.
   Google Scholar
• MSCBS. Cobertura de vacunación de la primera y segunda dosis de VPH en mujeres. 2018 [accesssed 2019]. https://www.sanidad.gob.es/en/profesionales/saludPublica/prevPromocion/vacunaciones/calendario-y-coberturas/coberturas/docs/Todas_las_tablas2018.pdf.
   Google Scholar
• Australian Government Department of Health. Historical data from the national HPV vaccination program register.2019 [accesssed 2019]. https://www.health.gov.au/resources/collections/historical-data-from-the-national-hpv-vaccination-program-register.
   Google Scholar
• Costa APF, Cobucci RNO, da Silva JM, da Costa Lima PH, Giraldo PC, Gonçalves AK. Safety of human papillomavirus 9-valent vaccine: a meta-analysis of randomized trials. J Immunol Res. 2017;2017:3736201.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459–66.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, Moreira Jr ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. Erratum appears N Engl J Med. 2011 Apr 14;364(15):401–11.
   Google Scholar
• Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2014;372(8):711–23.
   Web of Science ®Google Scholar
• Cabasés Hita JM, Sánchez Iriso E, Ollo López A, Errea Rodríguez M. Encuesta Nacional de Salud. España 2011/12. Calidad de vida relacionada con la salud en adultos: EQ-5D-5L [Internet]; 2014. https://www.msssi.gob.es/estadEstudios/estadisticas/encuestaNacional/encuestaNac2011/informesMonograficos/CVRS_adultos_EQ_5D_5L.pdf.
   Google Scholar
• Soler Soneira M, Olmedo Lucerón C, Sánchez-Cambronero Cejudo L, Cantero Gudino E, Limia Sánchez A. El Coste de vacunar a lo largo de toda la vida en España. Rev Esp Salud Publica. 2020;94:18–20.
   Google Scholar
• Diaz M, Moriña D, Rodríguez-Salés V, Ibáñez R, Espinás JA, de Sanjosé S. Moving towards an organized cervical cancer screening: costs and impact. Eur J Public Health. 2018;28:1132–38.
   PubMed Web of Science ®Google Scholar
• Mar J, Errasti J, Soto-Gordoa M, Mar-Barrutia G, Martinez-Llorente JM, Domínguez S, García-Albás JJ, Arrospide A. Valoración Del coste económico del cáncer colorrectal según estadio tumoral. Cir Esp. 2017;95:89–96.
   PubMedGoogle Scholar
• López N, Gil-de-Miguel Á, Pascual-García R, Ramón Y Cajal JM, Gil-Prieto R. Hospitalization burden associated with malignant neoplasia and in situ carcinoma in vulva and vagina during a 5-year period (2009–2013) in Spain: an epidemiological study. Papillomavirus Res. 2018;5:80–86.
   PubMed Web of Science ®Google Scholar
• Gil-Prieto R, Ester PV, Álvaro-Meca A, San Martín Rodŕiguez M, De Miguel ÁG. The burden of hospitalizations for head and neck neoplasm in Spain (1997-2008): an epidemiologic study. Hum Vaccines Immunother. 2012;8:788–98.
   PubMed Web of Science ®Google Scholar
• Castellsagué X, Rémy V, Puig-Tintoré L, de la Cuesta R, Gonzalez-Rojas N, Cohet C. Epidemiology and costs of screening and management of precancerous lesions of the cervix in Spain. J Low Genit Tract Dis [Internet]. 2009;13:38–45. [accessed 2021 Oct 8]. https://pubmed.ncbi.nlm.nih.gov/19098605/.
   PubMed Web of Science ®Google Scholar
• Larrañaga I, Millas J, Soto-Gordoa M, Arrospide A, San Vicente R, Irizar M, Lanzeta I, Mar J. The impact of patient identification on an integrated program of palliative care in Basque Country. Aten Primaria. 2019;51:80–90.
   PubMed Web of Science ®Google Scholar
• Oblikue Consulting S. Base de datos de costes sanitarios y ratios coste-efectividad españoles: eSalud [Internet]. [accessed 2020 Dec 1]. http://www.oblikue.com/bddcostes/.
   Google Scholar
• Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ [Internet]. 2018;27(4):746–61. doi:10.1002/hec.3633.
   PubMed Web of Science ®Google Scholar
• Marur S, Souza GD’, Westra WH, Forastiere AA, Professor A, Hopkins J. HPV-associated head and neck cancer: a virus-related cancer epidemic – a review of epidemiology, biology, virus detection and issues in management. Lancet Oncol. 2010;11:781–89.
   PubMed Web of Science ®Google Scholar
• Daley EM, Vamos CA, Thompson EL, Zimet GD, Rosberger Z, Merrell L, Kline NS. The feminization of HPV: how science, politics, economics and gender norms shaped U.S. HPV vaccine implementation. Papillomavirus Res. 2017;3:142–48.
   PubMed Web of Science ®Google Scholar
• Joint Commitee on Vaccination and Immunisation. JCVI interim statement on extending HPV vaccination to adolescent boys. London: The Joint Committee on Vaccination and Immunisation; 2017. p. 1–21.
   Google Scholar
• Joint Commitee on Vaccination and Immunisation. Statement on HPV vaccination joint committee on vaccination and immunisation. London: The Joint Committee on Vaccination and Immunisation; 2018.
   Google Scholar
• Datta S, Pink J, Medley GF, Petrou S, Staniszewska S, Underwood M, Sonnenberg P, Keeling MJ. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK. BMC Infect Dis. 2019;19(1):552. doi:10.1186/s12879-019-4108-y.
   PubMedGoogle Scholar
• O’Mahony JF, Paulden M. The joint committee on vaccination and immunisation’s advice on extending human papillomavirus vaccination to boys: were cost-effectiveness analysis guidelines bent to achieve a politically acceptable decision? Value Heal. 2019;22:1227–30.
   PubMed Web of Science ®Google Scholar
• Qendri V, Bogaards JA, Berkhof J. Pricing of HPV vaccines in European tender-based settings. Eur J Heal Econ. 2019;20:271–80.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygård M, Sundström K, Dillner J, Tryggvadottir L, Munk C, Berger S, Enerly E, Hortlund M, Ágústsson ÁI, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. EClin Med. 2020;23:100401.
   PubMedGoogle Scholar
• Mennini FS, Bonanni P, Bianic F, de Waure C, Baio G, Plazzotta G, Uhart M, Rinaldi A, Largeron N. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost Eff Resour Alloc. 2017;15(1):11. doi:10.1186/s12962-017-0073-8.
   PubMedGoogle Scholar
• Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2017;17(1):85–98. doi:10.1080/14737167.2016.1208087.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Joshi S, Muwonge R, Esmy PO, Basu P, Prabhu P, Bhatla N, Nene BM, Shaw J, Poli URR, et al. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early Find Ind Stud Vaccine. 2018;36:4783–91.
   PubMed Web of Science ®Google Scholar
• Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Lucas E, Verma Y, Esmy PO, Poli URR, Shah A, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol [Internet]. 2021;22(11):1518–29. [accessed 2021 Nov 18]. https://pubmed.ncbi.nlm.nih.gov/34634254/.
   PubMed Web of Science ®Google Scholar